SCHEMBL4077456

SCHEMBL4077456

Cc1[nH]c(=O)c2ccccc2c1C1CCCN1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 5/20 0.40
CHRM3 P20309 5/20 0.40
CHRM2 P08172 5/20 0.40
CHRM1 P11229 4/20 0.40
CHRM4 P08173 4/20 0.40
PARP1 P09874 4/20 0.39
TAAR1 Q96RJ0 2/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
TNKS O95271 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
GPR3 P46089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073365 0.82 CYP1A2 (0.47) CHRM5CHRM3CHRM2CHRM1CHRM4
SCHEMBL4079214 0.82 PARP1 (0.40) CHRM5CHRM3CHRM2CHRM1CHRM4
SCHEMBL4077380 0.77 HTR2C (0.51) PARP1
SCHEMBL4077282 0.73 HTR2C (0.44) PARP1
SCHEMBL4069626 0.72 HTR2A (0.56) PARP1KDM4ETNKSTNKS2
SCHEMBL4072381 0.71 HTR2A (0.49) CHRM5CHRM3CHRM2CHRM1CHRM4
SCHEMBL1082844 0.69 TAAR1 (0.40) CHRM5CHRM3CHRM2CHRM1CHRM4
SCHEMBL4076769 0.69 PARP1 (0.57) PARP1
SCHEMBL4075900 0.69 HTR2A (0.49) PARP1KDM4ETNKSTNKS2
SCHEMBL28525725 0.69 CHRM2 (0.49) CHRM5CHRM3CHRM2CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 CHRM5 4464/4885CHRM3 4118/4885CHRM2 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.